Treatment for Anemia, Sickle Cell

Recruiting · 18+ · All Sexes · New York, NY

This study is evaluating whether a medication may help reduce the symptoms of sickle cell disease.

See full description

About the trial for Anemia, Sickle Cell

Eligible Conditions
Anemia, Sickle Cell · Sickle Cell Disease (SCD)

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Control Group 1
Control Group 2


This trial is for patients born any sex aged 18 and older. There is one eligibility criterion to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Do not have asthma (see
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Baseline and one year
Screening: ~3 weeks
Treatment: Varies
Reporting: Baseline and one year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Baseline and one year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 30 secondary outcomes in patients with Anemia, Sickle Cell. Measurement will happen over the course of Baseline and one year.

Hemoglobin level
Change in Hemoglobin level at one year compared to baseline. Hemoglobin is a clinical lab test
Plasma Free Hemoglobin level
Change in Free Hemoglobin level at one year compared to baseline. Free hemoglobin is a direct measure of hemolysis. It is more reflective of hemolytic burden than reticulocyte count but it is not available for clinical use.
Multiplex Cytokine Panel Serum
Change in Multiplex Cytokine Panel Serum at one year compared to baseline. Key inflammatory mediators including interleukins, selectins, interferon and TNF.
Whole Blood Immune Cell Subpopulations CyTOF
Change in Whole Blood Immune Cell Subpopulations CyTOF at one year compared to baseline. Frequencies of all immune subpopulations will be calculated to identify pulmonary inflammation signatures.
O-Link Inflammation Panel Sputum
Change in O-Link Inflammation Panel Sputum at one year compared to baseline. Inflammation panel performed on sputum supernatant will be a measure of pulmonary inflammatory signatures
O-Link Inflammation Panel Serum
Change in O-Link Inflammation Panel Serum at one year compared to baseline. A 92 analyte panel of key molecules involved in inflammation
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is anemia, sickle cell?

Anemia is a condition that frequently occurs in people with sickle cell disease, characterized by a significant reduction in the production of red blood cells. Because of this, the red cells in the circulation are characterized by a marked decrease in oxygen-transmission with consequent symptoms.

Anonymous Patient Answer

What are the signs of anemia, sickle cell?

Signs of anemia include fatigue, lightheadedness and nausea, as well as a rapid heart rate, a dull pulse and dizziness. A sickle cell trait may also give such signs.\n

Anonymous Patient Answer

Can anemia, sickle cell be cured?

A well-controlled clinical trial demonstrates that children with SCA have a normal rate of transfusions until 9 years of age. Older children develop less severe symptoms with increasing hemoglobin levels, indicating the natural history of the disease may change over time. This highlights the need for the development of strategies that delay the onset of disease and maintain the excellent functional outcomes that may be achieved if anemia is adequately addressed.

Anonymous Patient Answer

What causes anemia, sickle cell?

In sub-Saharan Africa, anemia is common and is commonly due to sickle cell disease. Efforts to implement effective control of sickle cell disease are needed.

Anonymous Patient Answer

How many people get anemia, sickle cell a year in the United States?

The prevalence of anemia, sickle cell a year in the United States is more than one-half of the entire black population; it is also four times higher than in white men and women. More than three-fifths of the women also have sickle cell trait. The prevalence of the trait increases with age: in black women, the prevalence of sickle cell trait increases from 14 percent in women < 45 years old to 80 percent in women > 45 years old.

Anonymous Patient Answer

What are common treatments for anemia, sickle cell?

All cases of sickle cell disease should be treated for anemia to minimize complications. The National Institutes of Health (NIH) recommends that women of child-bearing age who are considering pregnancy take folic acid and iron pills to prevent spina bifida (a birth defect where one or more nerve roots or the spinal cord are twisted) resulting in a deformed foot (dwarf foot in the U.S.), or an abnormal posture (a low position of the rib cage resulting in a sunken chest), or other neurological disorders such as mental illness (mental retardation). Pregnancies where spina bifida has occurred before birth often result in serious complications of the fetus.

Anonymous Patient Answer

What is the latest research for anemia, sickle cell?

The recent studies showed that the sickle cell phenotype of patients does not play a role in the pathophysiology of malaria and that it is probably caused by the action of the antimalarial drug mefloquine. At least three of five previously reported studies on sicklecell anemia were flawed or not fully reported in the peer-reviewed literature. The authors recommend that further studies of this common pediatric condition are well designed and that reported findings from the peer-reviewed literature should be carefully considered.

Anonymous Patient Answer

Who should consider clinical trials for anemia, sickle cell?

Clinically applicable clinical trials for anemia, sickle cell, and/or transfusion of blood products are needed to prevent the most severe morbidity and mortality that may be due to this disease. Such studies should also be tailored to address specific clinical questions pertinent to anemic and/or sickle cell disease in this patient population.

Anonymous Patient Answer

Does anemia, sickle cell run in families?

Findings from a recent study underscore the need for further research to examine anemia risk in parents as a potential explanation for the familial clustering of sickle cell anomalies in their children.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

The findings of the present meta-analysis, including a good quality of evidence, support the hypothesis that a trial with a comparator that can be blinded is likely to yield more useful evidence in meta-analyses than an open-label trial.

Anonymous Patient Answer

Is treatment safe for people?

There are few reports that have evaluated treatment for people with SCD. However, a small number of reports show that SCD is unlikely to cause problems unless treatment is ineffective. Treatment has the potential to delay puberty, increase susceptibility to serious infections, and affect development of other organ systems. [Level of evidence: C.

Anonymous Patient Answer

What is treatment?

In a recent study, findings points to a number of things that can be done to improve outcomes and patient management. It underscores the need for more education of patients with SCD regarding the signs and symptoms of the disease, especially as it relates to anemia, to help optimize their management to minimize complications and prevent damage to the heart, vital signs, and long-term quality of life. It also highlights the urgent need for a standardized approach to management of hemoglobin thresholds and the value of routine visits with hematology/oncology specialists. Further research is needed to develop more effective educational models and tools to improve management.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Anemia, Sickle Cell by sharing your contact details with the study coordinator.